Merck & Co., Inc. (MRK)
| Market Cap | 277.02B +43.4% |
| Revenue (ttm) | 65.77B +2.9% |
| Net Income | 8.94B -48.8% |
| EPS | 3.58 -48.0% |
| Shares Out | 2.47B |
| PE Ratio | 31.37 |
| Forward PE | 13.11 |
| Dividend | $3.40 (3.03%) |
| Ex-Dividend Date | Mar 16, 2026 |
| Volume | 11,953,280 |
| Open | 112.33 |
| Previous Close | 109.18 |
| Day's Range | 111.88 - 114.54 |
| 52-Week Range | 73.31 - 125.14 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 125.29 (+11.71%) |
| Earnings Date | Apr 30, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $125.29, which is an increase of 11.71% from the latest price.
News
Merck & Co. Earnings Call Transcript: Q1 2026
Q1 revenue grew 5% year-over-year to $16.3 billion, led by oncology and animal health, but a $9 billion one-time charge resulted in a reported loss. Guidance for 2026 was raised, with continued investment in pipeline, new launches, and business development.
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NC...
Merck Sales Rise on Continued Keytruda Growth
Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow.
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales guidan...
Merck posts quarterly loss due to Cidara charge, sales rise 5%
Merck & Co on Thursday reported a loss for the first quarter as an acquisition-related charge offset a 5% increase in product sales driven by cancer and respiratory drugs.
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results.
Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with nine professional baseball teams and former professional ba...
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act o...
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
New collaboration taps Gemini Enterprise to realize business-driving value, innovation and patient impact across the next era of biopharmaceutical growth LAS VEGAS, April 22, 2026 /PRNewswire/ -- Clou...
Merck to partner with Google Cloud on AI initiatives
Drugmaker Merck & Co said on Wednesday it will partner with Google Cloud to build up its artificial intelligence capabilities, investing as much as $1 billion with Google over a number of years to fu...
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany's Merck KGaA and Japan's Ono Pharmaceutical for an experimental cancer treatment that could be valued at more tha...
FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™...
US FDA approves Merck's combination HIV treatment
The U.S. Food and Drug Administration approved Merck's once-daily, oral, combination regimen for HIV infections, the health regulator's website showed on Tuesday.
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advance...
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) granted priority review for two...
European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck press release announcing European Commission approval of ENFLONSIA.
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and Merck's, known as MSD outside of the United States and Canada, (NYSE: MRK) Biologics License Application (BLA) for ifinatamab derux...
1Q26 Earnings: Where Street Estimates Are Too Low & Who Should Beat
GAAP earnings, despite popular opinion, don't accurately measure profits. Companies can, and do, manipulate GAAP earnings through accounting rule loopholes.
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding share...
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...